NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations

Insiders continue to Buy NeOnc (NASDAQ: NTHI) as it heads into a potentially important period for its clinical programs and FDA meetings

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.